99% up 5-Isothiocyanato-3-(Trifluoromethyl)Picolinonitrile 951753-87-0

Category:Intermediates > Pharmaceutical Intermediates
Product Name:99% up 5-Isothiocyanato-3-(Trifluoromethyl)Picolinonitrile 951753-87-0
CAS No.:951753-87-0
Standard:USP, BP, EP, JP, In-house Standards
Price(USD):Negotiable
Company:Sinoway Industrial Co.Ltd.

Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Xiamen, Fujian

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

  • Monthly Production Capacity: 1000kg

    Packaging Information: 1kg/bottle

  • Delivery Lead Time: 7 days after payment

    Sample Provided: yes

    Payment Terms: L/L

     

    Product Information

     

    Product name

    5-isothiocyanato-3-(trifluoromethyl)picolinonitrile /

    Apalutamide intermediate

    CAS No.

    951753-87-0

    Molecular Formula

    C8H2F3N3S

    Molecular Weight

    229.18

    Quality Standard

    98% up by HPLC

    Appearance

    White powder

     

     

    Molecular Structure:

                                                           

    Synonyms:

    5-isothiocyanato-3-(trifluoromethyl)picolinonitrile

    Density:

    1.41±0.1 g/cm3(Predicted)

    Boiling Point:

    367.7±42.0 °C(Predicted)

    PSA:

    81.13000

    LogP:

    2.70638

     

     

    Usage

     

    5-isothiocyanato-3-(trifluoromethyl)picolinonitrile is one of key intermediates of apalutamide (N-1).

     

    Function of Apalutamide

    As a second-generation nonsteroidal androgen receptor inhibitory drugapalutamide can prevent the fusion of androgen and receptors, and block the transfer of AR to the nucleus of cancer cells. In addition, apalutamide can also control androgen and promote the growth of cancer cells.

     

    The safety and efficacy of apalutamide are based on a randomized clinical trial of 1,207 patients with non-metastatic, castration-resistant prostate cancer. Patients in the trial received apalutamide or placebo. All patients also received hormone therapy, either with a gonadotropin-releasing hormone (GnRH) analog, or with surgery to lower the amount of testosterone in the body (surgical castration). Median metastasis-free survival was 40.5 months for patients taking apalutamide, compared with 16.2 months for patients taking placebo. From the above experiments, we can see that the effect of apalutamide in the treatment of prostate cancer is very significant.

Send your message to this supplier
  • From:
  • To:
    Sinoway Industrial Co.Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service